Literature DB >> 20440588

Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified release products: workshop summary report.

Mei-Ling Chen1, Vinod P Shah, Derek Ganes, Kamal K Midha, James Caro, Prabu Nambiar, Mario L Rocci, Avinash G Thombre, Bertil Abrahamsson, Dale Conner, Barbara Davit, Paul Fackler, Colm Farrell, Suneel Gupta, Russell Katz, Mehul Mehta, Sheldon H Preskorn, Gerard Sanderink, Salomon Stavchansky, Robert Temple, Yaning Wang, Helen Winkle, Lawrence Yu.   

Abstract

Modified release products are complex dosage forms designed to release drug in a controlled manner to achieve desired efficacy and safety. Inappropriate control of drug release from such products may result in reduced efficacy or increased toxicity. This workshop provided an opportunity for pharmaceutical scientists from academia, industry, and regulatory agencies to discuss current industry practices and regulatory expectations for demonstrating pharmaceutical equivalence and bioequivalence of MR products, further facilitating the establishment of regulatory standards for ensuring therapeutic equivalence of these products.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20440588      PMCID: PMC2895434          DOI: 10.1208/s12248-010-9201-5

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  4 in total

1.  Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.

Authors:  J Swanson; S Gupta; D Guinta; D Flynn; D Agler; M Lerner; L Williams; I Shoulson; S Wigal
Journal:  Clin Pharmacol Ther       Date:  1999-09       Impact factor: 6.875

2.  Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

Authors:  Thomas Roth; Christina Soubrane; Laurence Titeux; James K Walsh
Journal:  Sleep Med       Date:  2006-07-03       Impact factor: 3.492

Review 3.  Seizures and bupropion: a review.

Authors:  J Davidson
Journal:  J Clin Psychiatry       Date:  1989-07       Impact factor: 4.384

Review 4.  Should bupropion dosage be adjusted based upon therapeutic drug monitoring?

Authors:  S H Preskorn
Journal:  Psychopharmacol Bull       Date:  1991
  4 in total
  7 in total

1.  Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.

Authors:  Enrique Seoane-Vazquez; Rosa Rodriguez-Monguio; Richard Hansen
Journal:  Clin Drug Investig       Date:  2016-04       Impact factor: 2.859

Review 2.  Using partial area for evaluation of bioavailability and bioequivalence.

Authors:  Mei-Ling Chen; Barbara Davit; Robert Lionberger; Zakaria Wahba; Hae-Young Ahn; Lawrence X Yu
Journal:  Pharm Res       Date:  2011-04-13       Impact factor: 4.200

3.  Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report.

Authors:  Mei-Ling Chen; Vinod P Shah; Daan J Crommelin; Leon Shargel; Dennis Bashaw; Masood Bhatti; Henning Blume; Jennifer Dressman; Murray Ducharme; Paul Fackler; Terry Hyslop; Lorelei Lutter; Jose Morais; Eric Ormsby; Saji Thomas; Yu Chung Tsang; Raja Velagapudi; Lawrence X Yu
Journal:  AAPS J       Date:  2011-08-16       Impact factor: 4.009

4.  Biopharmaceutical Evaluation and CMC Aspects of Oral Modified Release Formulations.

Authors:  Rong-Kun Chang; Neil Mathias; Munir A Hussain
Journal:  AAPS J       Date:  2017-07-05       Impact factor: 4.009

5.  Use of partial area under the curve metrics to assess bioequivalence of methylphenidate multiphasic modified release formulations.

Authors:  Ethan M Stier; Barbara M Davit; Parthapratim Chandaroy; Mei-Ling Chen; Jeanne Fourie-Zirkelbach; Andre Jackson; Stephanie Kim; Robert Lionberger; Mehul Mehta; Ramana S Uppoor; Yaning Wang; Lawrence Yu; Dale P Conner
Journal:  AAPS J       Date:  2012-09-14       Impact factor: 4.009

6.  Use of partial AUC (PAUC) to evaluate bioequivalence--a case study with complex absorption: methylphenidate.

Authors:  Jeanne Fourie Zirkelbach; Andre J Jackson; Yaning Wang; Donald J Schuirmann
Journal:  Pharm Res       Date:  2012-09-25       Impact factor: 4.200

7.  Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.

Authors:  M Lamba; M M Hutmacher; D E Furst; A Dikranian; M E Dowty; D Conrado; T Stock; C Nduaka; J Cook; S Krishnaswami
Journal:  Clin Pharmacol Ther       Date:  2017-02-09       Impact factor: 6.875

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.